BioAge Labs | Targeting metabolic aging
WEBJun 21, 2024 · Our human-first discovery platform analyzes proprietary multi-omics data captured over decades to identify the molecular mediators of aging and disease. Our pipeline programs target key pathways that drive metabolic aging based on novel insights from our platform.
Obesity drug developer BioAge seeks up to $587 mln valuation in …
WEB1 day ago · Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEB1 day ago · September 18, 2024 at 4:53 PM EDT. Save. BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 ...
Obesity drugmaker BioAge targets $158 million in IPO
WEB1 day ago · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a ...
Obesity drug developer BioAge seeks up to $587 million ... - Yahoo
WEB17 hours ago · (Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a ...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEBBioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement. The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday with the US Securities and Exchange Commission.
BioAge Labs | Company
WEBBioAge takes a human-centric, data-driven approach to identify the molecular features of healthy aging and reveal the causes of age-related diseases.
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
WEBSep 3, 2024 · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering.
BioAge Labs | Pipeline - Discovery
WEBDisc. Our lead program, azelaprag, has potential to be a first and best-in-class oral weight loss therapy co-administered with GLP-1 to achieve injectable-like total weight loss and improved body composition.
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class …
WEBOct 26, 2023 · By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or even prevent age-related disease in entirely new...